Chinese biotechs MediLink Therapeutics (Suzhou) Co., Ltd and Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) have entered into a collaboration and license agreement. MediLink’s TMALIN antibody drug conjugate (ADC) platform will be utilized to develop ZL-6201, a novel LRRC15-targeted ADC drug discovered by Zai Lab, for the treatment of solid tumors. No financial details were disclosed.
Collaboration Details
Zai Lab, aiming to bolster its global oncology pipeline through this deal, expects to file an Investigational New Drug (IND) application for ZL-6201 in 2025. The drug has yielded promising results in pre-clinical studies, indicating its potential as a new treatment option for solid tumors.
Significance of the Collaboration
This collaboration between MediLink Therapeutics and Zai Lab highlights the growing trend of strategic partnerships in the biotech industry, particularly in the development of innovative oncology treatments. By leveraging MediLink’s ADC platform, Zai Lab aims to accelerate the development of ZL-6201, potentially improving outcomes for patients with solid tumors.-Fineline Info & Tech
